Why play the clinical guessing game when attempting to tap into the growth of the biotech industry? Companies such as Amgen, Ligand Pharmaceuticals, Protalix, and Repligen are tapping into long term trends without much of the risk.
News & Analysis: Protalix BioTherapeutics
Protalix’s joint venture with Pfizer to bring a new Gaucher disease treatment to the market has had a rough start. Is the company doomed to be buried by its entrenched rivals, Sanofi and Shire?
The latest results in Protalix's pipeline may be from a phase 1 trial, but don't let that fool you. If successful, PRX-112 could run laps around Shire and Sanofi and catch the attention of larger partners, including Pfizer.
Does disruptive potential trump poor finances for this developmental-stage company?
A debt offering sent shares south. How far can the extra cash take this biotech?
These five stocks posted double-digit declines this past week.
A quirk in patent laws handed Enbrel exclusivity through 2028, but the competition isn't wasting any time.
These companies are stuffed full of potential, but may be lacking in the results department. They could still pay off for investors.
A look back at the biggest stories this week in biotech and what they mean for investors.
Protalix is exploring its options.